Abiraterone acetate is primarily used in the treatment of metastatic castration-resistant prostate cancer. It works by inhibiting the enzyme CYP17A1, which blocks the production of androgens—hormones that can promote the growth of prostate cancer cells. This medication is often administered orally in combination with prednisone to enhance its effectiveness and mitigate side effects associated with androgen deprivation. It has demonstrated significant efficacy in extending survival and improving quality of life for patients with advanced disease. Its use is carefully monitored by healthcare professionals to manage potential adverse effects and ensure optimal therapeutic outcomes.